Last reviewed · How we verify

KSI-101 — Competitive Intelligence Brief

KSI-101 (KSI-101) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific antibody. Area: Ophthalmology.

phase 3 Bispecific antibody VEGF and ANG-2 Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

KSI-101 (KSI-101) — Kodiak Sciences Inc. KSI-101 is a bispecific antibody that simultaneously targets VEGF and ANG-2 to reduce retinal inflammation and vascular leakage in retinal diseases.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
KSI-101 TARGET KSI-101 Kodiak Sciences Inc phase 3 Bispecific antibody VEGF and ANG-2
Elrexfio elranatamab Pfizer marketed Bispecific antibody BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells 2023-01-01
Elrexfio Elranatamab Pfizer marketed Bispecific antibody BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells 2023-01-01
Elrantamab elrantamab Pfizer marketed Bispecific Antibody BCMA (B-cell maturation antigen)
CHS-1420 CHS-1420 Coherus Oncology, Inc. phase 3 Bispecific antibody CD47 and CD40
M701 M701 Wuhan YZY Biopharma Co., Ltd. phase 3 Bispecific antibody
AK112, Gemcitabine, Cisplatin AK112, Gemcitabine, Cisplatin Akeso phase 3 Bispecific antibody (PD-1/LAG-3 inhibitor) combined with chemotherapy PD-1 and LAG-3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific antibody class)

  1. Shanghai Miracogen Inc. · 3 drugs in this class
  2. Atom Therapeutics Co., Ltd · 2 drugs in this class
  3. Pfizer · 2 drugs in this class
  4. Allergan · 1 drug in this class
  5. AstraZeneca · 1 drug in this class
  6. BioNTech SE · 1 drug in this class
  7. DualityBio Inc. · 1 drug in this class
  8. Coherus Oncology, Inc. · 1 drug in this class
  9. Genmab · 1 drug in this class
  10. Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). KSI-101 — Competitive Intelligence Brief. https://druglandscape.com/ci/ksi-101. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: